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ABSTRACT The N-end rule relates the metabolic stability
of a protein to the identity of its amino-terminal residue.
Previous work, using amino acid derivatives such as dipeptides
to inhibit N-end rule-mediated protein degradation in an
extract from mammalian reticulocytes, has demonstrated the
existence of specific N-end-recogniing proteins in this in vitro
system. We now show that these nontoxic amino acid deriva-
tives, when added to growing cells of the yeast Saccharomyces
cerevisiae, are able to inhibit the degradation of proteins by the
N-end rule pathway in vivo. Moreover, this inhibition is shown
to be selective for the two distinct classes of destabilizing
amino-terminal residues in substrates of the N-end rule path-
way.
At least some proteins are short-lived in vivo because they
contain sequences (degradation signals) that make these
proteins substrates of specific proteolytic pathways. An
essential component ofone degradation signal is the protein's
amino-terminal residue (1). This degradation signal is mani-
fested as the N-end rule, which relates the metabolic stability
ofa protein to the identity of its amino-terminal residue (1-8).
Similar but distinct versions of the N-end rule operate in
mammals (2, 5, 8-11), yeast (1-5, 7, 12), and bacteria (J.
Tobias and A.V., unpublished results).
The N-end rule-based degradation signal in eukaryotes
comprises a destabilizing amino-terminal residue and a spe-
cific internal lysine residue (1-5, 8). The set of destabilizing
amino-terminal residues is organized hierarchically. Specif-
ically, amino-terminal Asp and Glu (and Cys in mammalian
reticulocytes) are secondary destabilizing residues in that
they are destabilizing through their ability to be conjugated to
Arg, aprimary destabilizing residue (1, 5-7). Amino-terminal
Asn and Gln are tertiary destabilizing residues in that they are
destabilizing through their ability to be converted, via selec-
tive deamidation, into the secondary destabilizing residues
Asp and Glu (5).
Previous work (1) has predicted the existence of "N-end-
recognizing" proteins that select potential proteolytic sub-
strates by binding to their amino-terminal residues. N-end-
recognizing proteins have recently been detected in an in
vitro ubiquitin-dependent proteolytic system derived from
mammalian reticulocytes, and identified as the E3 proteins
that were previously shown to bind proteolytic substrates
prior to their ubiquitination by a subset of ubiquitin-
conjugating (E2) enzymes (5, 9, 10, 12, 13). Three distinct
types of E3 activity have been detected in the reticulocyte-
derived in vitro system by using assays based on selective
inhibition of the degradation of specific proteins by dipep-
tides bearing different destabilizing amino-terminal residues.
The type I E3 activity is specific for the positively charged
destabilizing amino-terminal residues Arg, Lys, and His (5,
9). The type II activity is specific for the bulky hydrophobic
destabilizing amino-terminal residues Phe, Trp, Tyr, and Leu
(and lie in yeast) (5, 9). The type III activity is specific for the
amino-terminal residues Ala, Ser, and Thr, which share the
properties of small size and lack of charge (5). Ala, Ser, and
Thr are destabilizing in reticulocytes but stabilizing in yeast,
implying that Saccharomyces cerevisiae lacks type III E3
activity (1, 5).
The efficient and selective inhibition of the N-end rule
pathway by amino acid derivatives in reticulocyte extract has
prompted us to ask, using S. cerevisiae as a model system,
whether a similar approach is feasible with intact cells. The
ability to perturb the N-end rule pathway in vivo would
provide a powerful tool for studies of this pathway, especially
in organisms where genetic analysis is difficult, and might
also prove useful in pharmacological and biotechnological
applications. We show that the in vivo inhibition of the N-end
rule pathway with amino acid derivatives is feasible and
should be generally applicable.
METHODS
Amino Acid Derivatives, Yeast Strains, and Expression
Vectors. Amino acid derivatives were obtained from Bachem
Bioscience or Sigma and stored as either 0.2 M (dipeptide) or
1 M [leucine methyl ester (Leu-OMe)] solutions in synthetic
defined (SD)-galactose medium [2% galactose, 0.67% yeast
nitrogen base without amino acids (Difco), adenine (10 Ag/
ml), and other auxotrophic nutrients (14)] containing in
addition 0.2 M potassium phosphate buffer (pH 7.0). In the
inhibition experiments, control yeast cultures received
equivalent amounts of potassium phosphate buffer in SD-
galactose; the addition ofbuffer alone did not affect the levels
of Xaa-p-galactosidase (X-,Bgal) proteins (data not shown).
The L-Arg-D-Ala dipeptide was custom-synthesized and pu-
rified by Bachem Bioscience.
S. cerevisiae strain BWG1-7a (MATa his4 ura3 adel leu2)
(15) transformed with 2A-based vectors expressing ubiquitin-
X-,3gal (Ub-X-I8gal) fusion proteins from the galactose-
inducible GAL] promoter (1-3) was grown at 30'C in SD-
galactose medium (14).
(Igal Assay. Yeast cells were pelleted by centrifugation at
12,000 x g for 20 sec and resuspended in an equal volume of
Z buffer (35 mM 2-mercaptoethanol/10 mM KCI/0.1 M
potassium phosphate, pH 7.0). Aliquots from the suspension
were diluted to 0.5 ml with Z buffer, followed by the addition
of 20 p1l ofCHC13 and 20 ,ul of0.1% SDS. The suspension was
mixed with a Vortex mixer at top speed for 10 sec; pgal
activity assays were then initiated (at 300C) by adding 0.1 ml
ofo-nitrophenyl f3-D-galactoside (4 mg/ml) and terminated by
adding 0.5 ml of 1 M Na2CO3. The samples were centrifuged
at 12,000 x g for 2 min and the OD420 of the supernatants was
determined. .3gal activity was calculated from OD420 readings
normalized to cell density and the length of assay (16).
Abbreviations: ,tgal, f3-galactosidase; X-,8gal, ,Bgal bearing an amino-
terminal residue X; Ub-X-,Bgal, ubiquitin-X-,3gal; Leu-OMe, leucine
methyl ester.
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Pulse-Chase Analysis. Pulse labeling with [35S]methionine,
nonradioactive chase, extraction, immunoprecipitation with
a monoclonal antibody to ,gal, and electrophoretic analysis
were carried out as described (1) except that cells were
harvested by centrifugation at 2000 x g for 5 min, rather than
by filtration, and that exponentially growing cultures (OD6w
< 1) were used. To determine the degradation kinetics of
X-,8gal proteins, their electrophoretic bands were excised
from scintillant-impregnated gels, and I'S in the bands was
determined.
RESULTS AND DISCUSSION
Effects of Amino Acid Derivatives on the in Vivo Levels of
X-.Bgal Proteins. Preliminary experiments showed that, as
expected (17), yeast cells can take up amino acid derivatives
from their growth medium, because histidine in SD medium
(14) could be replaced by an equimolar amount of the
dipeptide His-Ala (all amino acids are L stereoisomers unless
stated otherwise) to support the growth of histidine auxo-
trophs. Similarly, either Leu-Leu or Leu-OMe could substi-
tute for leucine in supporting the growth of leucine auxo-
trophs (data not shown), implying that amino acid derivatives
are converted, presumably after uptake, into the correspond-
ing amino acids.
We next asked whether amino acid derivatives, once taken
up by the cell, could inhibit the N-end rule pathway in vivo.
The model substrates used were derivatives of Escherichia
coli 8gal. In eukaryotes, Ub-X-/3gal fusion proteins are
precisely deubiquitinated either in vivo or in cell-free extracts
by an endogenous Ub-specific processing protease to yield
X-,Bgal proteins bearing the residue X at the amino terminus
(1, 5). Depending on the identity ofX, the X-/3gal proteins are
either long-lived or metabolically unstable, with destabilizing
amino-terminal residues conferring short half-lives on the
corresponding X-fBgal proteins (1-8).
In preliminary experiments, yeast expressing various Ub-
X-fBgal proteins were plated on SD-galactose medium con-
taining amino acid derivatives and the chromogenic fgal
substrate 5-bromo-4-chloro-3-indolyl B-D-galactoside (see
Methods and ref. 14). The results (not shown) were consistent
with the possibility, to be confirmed below, that certain
amino acid derivatives (but not equimolar amounts of their
constituent free amino acids) could increase steady-state
levels of normally short-lived X-fBgal proteins. These effects
were quantified by measuring the enzymatic activity of
intracellular X-pgal proteins as a function of either the
intracellular concentration ofan amino acid derivative or the
elapsed incubation time. An initial experiment (Fig. LA)
indicated that the effect of Leu-OMe (10 mM) on the level of
Leu-8gal was stronger with exponentially growing cells
(OD6w < 1). Further analyses were carried out with such
cells.
The maximal effect of Leu-OMe (after 1 hr of incubation)
on the levels of X-,Bgal proteins with type II (bulky hydro-
phobic) destabilizing amino-terminal residues (5, 9) was
reached at -10 mM Leu-OMe (Fig. 1B). This maximally
effective concentration was approximately the same for all of
the type II destabilizing residues [Leu, Trp, and Tyr (Fig.
1B); Phe and Ile (data not shown)]. Notably, the level of
Arg-,8gal, which bears a type I (positively charged) destabi-
lizing amino-terminal residue (5, 9), was unaffected by Leu-
OMe (Fig. 1 A and B). At 10 mM, neither Leu-OMe nor
dipeptides (see below) influenced the appearance (under a
phase-contrast microscope) or growth rate of yeast cells (data
not shown).
The level of Leu-fBgal in cells was found to increase, over
a period of at least 8 hr, in direct proportion to the length of
incubation with Leu-OMe at 10 mM (Fig. 1C). As a result,
after 8 hr of incubation with Leu-OMe, the level of Leu-p3gal
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FIG. 1. Inhibition of the N-end rule pathway in vivo. (A) Levels
of Leu-fBgal and Arg-flgal as functions of cell density in S. cerevisiae
cultures in the presence or absence of Leu-OMe. Strain BWG1-7a
expressing Ub-Leu-,gal (o, *) or Ub-Arg-fpgal (o, *) was grown in
SD-galactose at 30°C. At different cell densities, Leu-OMe was
added to halfofeach culture (n, *) to a final concentration of 10 mM,
incubation was continued for 3 hr, and f3gal activity was determined
and plotted against the final OD6w (see Methods). (B) Effect of
varying extracellular Leu-OMe concentration on steady-state levels
of X-,Bgal. Strain BWG1-7a expressing Ub-Arg-,8gal (o), Ub-Leu-
,fgal (n), Ub-Trp-fgal (o), or Ub-Tyr-3gal (x) was grown as in A to
OD6w of -1.0. Leu-OMe was then added to yield the indicated
concentration, incubation was continued for 1 hr, and 83gal activity
was determined. (C) Time dependence and reversibility of the
Leu-OMe effect on the level ofLeu-pgal. Strain BWG1-7a expressing
Ub-Leu-.gal was grown as inA to OD6N of 0.5. Leu-OMe was then
either added to 10 mM (n) or not added (o), and f8gal activity was
determined over the next 8 hr of growth in the same medium. After
4 hr of growth, cells from half the culture containing Leu-OMe were
collected by centrifugation, washed, resuspended, and grown further
in SD-galactose lacking Leu-OMe (A). (D) Time dependence and
reversibility of the effect of Arg-containing dipeptides on the level of
Arg-,Bgal. Strain BWG1-7a expressing Ub-Arg-figal was grown as in
A to OD6w of -0.5, followed by the addition of either Arg-Ala (to 10
mM; e), Ala-Arg (to 10 mM; o) or peptide-free buffer (see Methods)
(o), and further growth for 8 hr. Cells from half the culture containing
Arg-Ala were collected by centrifugation, washed, resuspended, and
grown further in SD-galactose lacking Arg-Ala (v).
in cells was -70-fold higher than that in cells from a parallel
culture grown in the absence ofLeu-OMe (Fig. 1C). The rate
of increase in the level of Leu-fBgal became progressively
slower after 8 hr in the presence of Leu-OMe (data not
shown).
The amount of Arg-fBgal in cells increased -55-fold over its
normal steady-state level after 8 hr of incubation with Arg-
Ala dipeptide at 10 mM (Fig. 1D). Crucially, Ala-Arg, a
dipeptide of the same composition as Arg-Ala but with a
stabilizing amino-terminal residue, had no effect on the in
vivo level of Arg-,Bgal (Fig. 1D), in agreement with the earlier
observations in reticulocyte extract (5, 9) that the identity of
the amino-terminal residue in a dipeptide determines its
specificity and activity in the inhibition of the N-end rule
pathway. [That Ala-Arg had actually been taken up by cells
was indicated by its ability to support the growth of an
arginine auxotroph (data not shown).] The in vivo inhibition
of X-3gal degradation by amino acid derivatives was com-
pletely reversible: removal of an inhibitor from the medium
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caused a gradual decrease ofthe previously elevated levels of
either Leu-f3gal or Arg-P3gal down to the levels in control
cultures (Fig. 1 C and D).
The addition of the Arg-Ala dipeptide to growing yeast
cells metabolically stabilized Arg-, Lys-, and His-f3gal but not
the X-Pgal proteins bearing bulky hydrophobic (type II)
destabilizing amino-terminal residues (Leu, Phe, Trp, Tyr, or
Ile). No X-jBgal proteins were stabilized by the Ala-Arg
dipeptide (Fig. 2). The Trp-Ala dipeptide, similarly to Leu-
OMe (Fig. 1B), metabolically stabilized Leu-, Phe-, Trp-,
Tyr-, and Ile-Pgal but did not have an effect on any other
X-f3gal tested, including Arg-, Lys-, and His-fgal (Fig. 2). No
X-f3gal proteins were stabilized by the Ala-Trp dipeptide (Fig.
2). These results provided in vivo evidence for the existence
of type I and type II primary destabilizing residues, a feature
of the N-end rule pathway originally defined in reticulocyte
extract (5, 9). [Ile is a "borderline" stabilizing residue in the
reticulocyte N-end rule but a type II primary destabilizing
residue in the yeast N-end rule (1, 3, 5). See ref. 5 for a
discussion of the distinction between stabilizing and desta-
bilizing residues in the N-end rule.]
The recent cloning of the gene (UBRI) for an N-end-
recognizing (E3) protein of S. cerevisiae has made possible in
vitro tests of the recognition specificity of this 225-kDa
protein (12). UBR1 specifically binds in vitro to proteins
bearing either type I or type II primary destabilizing amino-
terminal residues but does not bind to otherwise identical
proteins bearing stabilizing amino-terminal residues (12).
Similar conclusions have been reached from the analysis of
the partially purified counterpart of UBR1 from rabbit retic-
ulocytes (18). Since the type I and type II binding activities
500 r-
can be inhibited independently in the yeast UBR1 in vivo
(Fig. 2) and in a mammalian counterpart of UBR1 in vitro (5,
9, 18), it is likely that the corresponding binding sites are
distinct in both of these proteins.
The Arg-Ala dipeptide, while increasing the levels of
X-Pgal proteins bearing type I (basic) destabilizing amino-
terminal residues (Fig. 2), decreased the levels of X-fSgal
proteins bearing type II (bulky hydrophobic) destabilizing
amino-terminal residues. For instance, after 3 hr in the
presence of Arg-Ala, the levels of Tyr-,8gal and Leu-f8gal
were decreased, respectively, to =80% and =30%o of their
levels in the absence of the dipeptide (Fig. 2 and data not
shown). The "converse" effect was not observed, however:
Trp-Ala, while increasing the levels of X-f3gal proteins bear-
ing type II destabilizing residues, did not affect the levels of
X-,Bgal proteins bearing type I destabilizing residues (Fig. 2).
These in vivo data with yeast cells corroborated the analo-
gous in vitro findings with reticulocyte extracts (5, 9). One
interpretation of these results is that dipeptides with type I
(basic) amino-terminal residues inhibit the degradation of
endogenous substrates with basic amino termini in both yeast
cells and reticulocyte extract and thereby reduce competition
for some limiting component of the N-end rule pathway.
Since binding sites for the type I and type II primary
destabilizing amino-terminal residues are located within the
same protein (see above), an alternative possibility is that
occupation of a type I binding site in either a yeast or a
reticulocyte N-end-recognizing protein increases the effi-
ciency of recognition by that protein of type II proteolytic
substrates, whereas occupancy of the type II binding site
does not enhance the recognition of type I substrates.
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In addition to stabilizing Arg-, Lys-, and His-f3gal, the
Arg-Ala (but not Ala-Arg) dipeptide metabolically stabilized
Asp-pgal and Asn-f3gal, which bear, respectively, a second-
ary and a tertiary destabilizing amino-terminal residue (Fig.
2; see Introduction for terminology). This result provided an
in vivo confirmation of the hierarchical organization of the
N-end rule, in which a secondary (and after deamidation, a
tertiary) destabilizing residue is conjugated, via Arg-tRNA-
protein transferase, to arginine, a type I primary destabilizing
residue (5-7).
Independent in vivo confirmation of these aspects of the
N-end rule was provided by the recent cloning of the S.
cerevisiae genes ATE) and DEAl, which encode, respec-
tively, Arg-tRNA-protein transferase (7) and a deamidase
specific for amino-terminal Asn and Gln (unpublished re-
sults). As expected from the hierarchical structure of the
N-end rule (5), null deal mutants are unable to degrade
substrates that start with tertiary destabilizing residues (Asn
or Gln), whereas null ate] mutants are unable to degrade
substrates that start with either tertiary (Asn or Gln) or
secondary (Asp or Glu) destabilizing residues (ref. 7 and
unpublished data).
Recently, Kopitz et al. (19) reported that a short-lived
enzyme, ornithine decarboxylase, could be arginylated in
extracts from rat hepatocytes by an endogenous Arg-tRNA-
protein transferase, and furthermore, that the in vivo degra-
dation of ornithine decarboxylase in hepatocytes could be
partially suppressed by the tripeptide Glu-Val-Phe, a sub-
strate of Arg-tRNA-protein transferase. While still indirect,
these results suggest that ornithine decarboxylase is a sub-
strate of the N-end rule pathway that bears a secondary or a
tertiary destabilizing amino-terminal residue. If so, it should
now be possible to use amino acid derivatives to inhibit, in
vivo, both the amino-terminal modification of such proteins
and their subsequent recognition by E3.
One parameter that is expected to determine the effective-
ness of an amino acid derivative as an in vivo inhibitor of the
N-end rule pathway is the derivative's metabolic stability. To
see whether making a dipeptide more resistant to proteolytic
cleavage would augment its inhibitory effect, we tested the
dipeptide L-Arg-D-Ala, whose second residue is a D-stereo-
isomer, and found that this dipeptide was more effective in
raising steady-state levels of the relevant short-lived X-/3gal
proteins than was the Arg-Ala dipeptide in which both
residues are L-stereoisomers (Fig. 2). Whether the greater
effectiveness of L-Arg-D-Ala is due to its (expected) longer
half-life in vivo or to other reasons, such as higher rate of
uptake, remains to be determined.
Metabolic Stabilization of X-,tgal Proteins in Vivo. Pulse-
chase analysis was used to follow the degradation of newly
formed X-,Bgal proteins in the presence or absence of amino
acid derivatives (Figs. 3 and 4). As noted previously (1, 3), the
in vivo degradation of X-,3gal proteins did not obey first-order
kinetics but instead slowed with time. More precisely, the
kinetics of degradation deviated from first order when suffi-
ciently long chase periods (>10 min at 30°C) were used (Fig.
4A). For chases shorter than 10 min (with 1-min pulses), the
degradation kinetics were close to first order for all of the
short-lived X-,Bgal proteins tested (Fig. 4 B and C; data not
shown).
The data of Figs. 3 and 4 confirmed that the increases in
steady-state levels of X-,8gal proteins in the presence of
relevant amino acid derivatives (Fig. 2) were due to metabolic
stabilization of normally short-lived X-f3gals. For instance,
the half-life of Leu-(3gal during the first 10 min of chase was
=3 min in the absence of Leu-OMe and -30 min in its
presence (Fig. 4B). Similarly, averaging over the first 10 min
of chase for Arg-,3gal (its in vivo degradation reproducibly
deviated from first-order kinetics even earlier than the deg-
radation of Leu-f8gal) yielded half-lives of -2 min in the
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FIG. 3. Pulse-chase analysis of X-,8gal degradation in the pres-
ence of amino acid derivatives. Exponential cultures of S. cerevisiae
strain BWG1-7a expressing Ub-Tyr-/3gal or Ub-Leu-pgal were la-
beled with [35S]methionine for 5 min at 30TC (lanes 0) followed by a
chase in the presence of unlabeled methionine (10 mM) and the
translation inhibitors cycloheximide and trichodermin for 10 and 30
min (lanes 10 and 30, respectively), extraction, immunoprecipitation,
and electrophoretic analysis of X-pgal (see Methods). Where indi-
cated, a 60-min (lanes 60) chase point was also taken. In the
experiments where amino acid derivatives were present (at 10 mM)
during growth, labeling, and chase, their names are shown above the
lanes. Identities of X-/3gal proteins are indicated at left. Arrowhead
denotes an "90-kDa long-lived 8gal cleavage product specific for
short-lived X-jBgal proteins (1, 4). Filled circle (at right) denotes an
-95-kDa long-lived ,gal cleavage product specific for long-lived
X-,fgal proteins (4). Asterisk denotes an unknown S. cerevisiae
protein that crossreacts with the monoclonal antibody to 8gal (1).
absence of the Arg-Ala dipeptide and =20 min in its presence
(Fig. 4C). [Northern hybridization analyses (data not shown)
indicated that the addition of amino acid derivatives did not
change the levels of mRNAs encoding the corresponding
X-,3gal proteins.] Pulse--chase analysis also detected two
further changes that have previously been shown to accom-
pany metabolic stabilization of X-jBgal proteins: the dimin-
ished accumulation of an -90-kDa ,Bgal cleavage product
specific for short-lived X-,gal species (1, 4), and the appear-
ance of an -95-kDa 8Bgal cleavage product specific for
long-lived X-f3gal species (4) (Fig. 3).
Another effect of the amino acid derivatives was an in-
crease in the amount of 35S in the pulse-labeled X-fPgal
species (a "zero-time" increase) that was especially pro-
nounced for the shorter-lived proteins such as Leu- and
Arg-l3gal (Fig. 3 and Fig. 4 B and C). The zero-time increase
was expected because metabolic stabilization ofa protein will
result in its greater net incorporation of label during a pulse
of constant duration, since a smaller fraction of the stabilized
protein is degraded during this time.
We do not understand the reasons for non-first-order
kinetics of X-fgal degradation in yeast (Fig. 4A, refs. 1 and
3, and data not shown). It was due neither to the use of
translation inhibitors during the chase [because similar re-
sults were obtained in the absence of inhibitors (M.
Hochstrasser, personal communication)] nor to other fea-
tures of the degradation assay, because in a similar in vivo
1094 Biochemistry: Baker and Varshavsky
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FIG. 4. Metabolic stabilization of X-f3gal proteins in the presence of amino acid derivatives. (A) Exponential cultures of S. cerevisiae strain
BWG1-7a expressing Ub-Tyr-.8gal and growing at 300C either in the absence (A) or in the presence (for 2 hr) of Leu-OMe at 10 mM (A) were
labeled with [35S]methionine for 5 min, followed by a chase, extraction, immunoprecipitation, and electrophoretic analysis of X-fBgal. Counts
per minute (cpm) shown on the ordinate axis are the actual cpm (minus background) in slices of a gel containing the bands of Tyr-f3gal (see
Methods). (B) Same as in A but with the pulse time of 1 min and with cells expressing Ub-Leu-fBgal either in the absence (o) or in the presence
(for 2 hr) of Leu-OMe at 10 mM (m). (C) Same as in B but with cells expressing Ub-Arg-,3gal and growing either in the absence (o) or in the
presence (for 2 hr) of Arg-Ala at 10 mM (0).
assay, the short-lived MATa2 repressor was degraded in
yeast with first-order kinetics (20). Among potential expla-
nations of the non-exponential X-flgal degradation is a hy-
pothesis that the assembly and "maturation" of an X-fgal
tetramer make it progressively more resistant to targeting
and/or degradation by the N-end rule pathway. Another
possible explanation is that an essential targeting component
of the N-end rule pathway has affinity for ribosomes, so that
a newly formed substrate of the N-end rule pathway, being in
the immediate vicinity of a ribosome, has a greater chance of
being targeted for degradation than the same substrate at later
times and farther away from the sites of translation.
Irrespective of its specific explanations, the non-first-order
kinetics of X-p8gal degradation makes it possible to account
for the apparent discrepancy between, for instance, an -10-
fold metabolic stabilization of Leu-fpgal by Leu-OMe in the
1-min pulse/10-min chase assay (Fig. 4B), and an n70-fold
increase in the level of the same Leu-/3gal after 8 hr of
incubation with Leu-OMe (Fig. 1C). Indeed, since the in vivo
degradation of an X-jSgal slows with time (Fig. 4A), a partial
metabolic stabilization by an amino acid derivative of more
recently formed (and hence shorter-lived) X-jBgal molecules
would increase the steady-state level ofan X-Pgal to a greater
extent than the same degree of metabolic stabilization of
"older" (and hence longer-lived) X-j8gal molecules. This
argument accounts for the relative increase of an "early"
half-life of an X-f3gal (Fig. 4 B and C) being lower than the
relative increase of its steady-state level in the presence of an
amino acid derivative (Fig. 1 C and D). (For a first-order
decay in the absence of changes in the rate of protein
synthesis, the relative increase of a protein's half-life equals
the relative increase in its maximal steady-state concentra-
tion.)
The ability to inhibit the N-end rule pathway in vivo may
have practical applications and, in addition, provides a pow-
erful tool for studies of this pathway.
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